Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2– Advanced Breast Cancer. The gene discussed is HR; the disease is breast cancer.